Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Patent
1996-12-19
1999-09-28
Eisenschenk, Frank C.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
5303883, 4352523, 4353391, 4242111, 4241471, 4241591, 4241331, C12N 500, C12N 120, C07K 1600, A61K 39155
Patent
active
059587652
ABSTRACT:
A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein .ltoreq.2.times.10.sup.-9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.
REFERENCES:
patent: 5411749 (1995-05-01), Mayo et al.
patent: 5476997 (1995-12-01), Kaneshima et al.
Uchibayashi, N. et al., Hybridoma, 14:313-321 (1995).
Carlsson, R. et al., J. Immunol., 148:1065-1071 (1992).
Satoh, N. et al., Immunol. Lett., 47:113-119 (1995).
Kudo, T. et al., Tohoku J. Exp. Med., 168:323-327 (1992).
Kudo, T. et al., Tohoku J. Exp. Med., 171:327-338 (1993).
Ifversen, P. & Borrebaeck, C.A.K., Seminars in Immunol., 8:243-248 (1996).
Ware, C.F. et al., J. Immunol. Meth., 85:353-361 (1995).
Trudel et al., Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection, Arch Virol 117:59-71, see connecting paragraphs, pp. 61-62 and 64-65, 1991.
Mosier et al., Transfer of a functional human immune system to mice with severe combined immunodeficiency, Nature, 335: 256-259, 1988.
McCune et al., The SCID-hu Mouse: Murine Model of the Analysis of Human Hematolymphoid Differentiation and Function, Science, 241, 1632-1639, 1988.
Gorny et al, Generation of human monoclonal antibodies to human immunodeficiency virus, PNAS, 86: 1624-1628, see Abstract, 1989.
Kozbor et al., Requirements for the establishment of high-titered human monoclonal antibodies against tetnus toxoid using the Epstein-Barr virus technique, J. Immunol., 127, 1275-1280, see Abstract, 1981.
Burton et al., A large array of human monclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 10134-10137, see Abstract and Materials and M, Nov. 19.
Paul, W.E., Fundamental Immunology, p. 242, 1993.
Seaver, Genetic Engineering, vol., 14(14), pp. 10 and 21, 1994.
Brams Peter
Morrow Phillip R.
Eisenschenk Frank C.
Idec Pharmaceuticals Corporation
Lidak Pharmaceuticals
Park Hankyel T.
LandOfFree
Neutralizing high affinity human monoclonal antibodies specific does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralizing high affinity human monoclonal antibodies specific , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing high affinity human monoclonal antibodies specific will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-702452